Search

Search Constraints

You searched for: Author/Creator Kligys, Kristina

Search Results

1. A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients With Ulcerative Colitis, Using the Pictorial Representation of Illness and Self-measure Tool. (29th July 2020)

2. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Issue 10 (18th September 2020)

3. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Issue 10 (27th February 2020)

4. Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study: 834. (October 2019)

6. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Issue 10340 (28th May 2022)

7. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Issue 10340 (28th May 2022)

8. S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn's Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy. (December 2022)

9. S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn's Disease. (October 2022)

10. S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn's Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction. (October 2022)